Should medicinal cannabis patients face zero-tolerance drug driving laws?

A policy analysis from Australia found that zero-tolerance THC driving laws disproportionately harm medicinal cannabis patients, whose road safety risks appear similar to or lower than those taking other legal prescription medications that impair driving.

Perkins, Daniel et al.·The International journal on drug policy·2021·Moderate EvidenceReview
RTHC-03427ReviewModerate Evidence2021RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Road safety risks associated with medicinal cannabis appear similar to or lower than numerous other potentially impairing prescription medications. Zero-tolerance THC laws criminalize patients who test positive for THC even when not impaired and using cannabis as prescribed. Some patients forgo needed medication to maintain driving access, while others face criminal sanctions despite following medical advice.

Key Numbers

Medical exemptions exist for other impairing drugs like methadone in Australia; THC presence-based offences apply regardless of impairment; comparable jurisdictions have implemented medical exemptions for cannabis

How They Did This

Policy analysis examining Australian regulatory approaches to potentially impairing prescription drugs versus illicit drugs, evidence on cannabis and road safety risk, patient impact data, and international comparisons of medicinal cannabis driving regulations.

Why This Research Matters

As countries legalize medical cannabis but maintain zero-tolerance driving laws based on THC detection (not impairment), patients face a cruel choice between medication and mobility. This analysis argues the inconsistency is rooted in cannabis's historical prohibition, not evidence.

The Bigger Picture

The tension between health policy (approving cannabis as medicine) and traffic policy (criminalizing any THC presence) creates an incoherent legal landscape. Other jurisdictions have resolved this through medical exemptions, demonstrating feasible alternatives to the Australian approach.

What This Study Doesn't Tell Us

Focused on Australian policy context. Does not provide new empirical data on driving impairment. Arguments rely on existing evidence base, which has limitations around cannabis and driving.

Questions This Raises

  • ?What level of THC correlates with meaningful driving impairment in regular medical users?
  • ?How do tolerance effects change the risk profile for daily medicinal cannabis patients?
  • ?Would impairment-based testing be more effective and equitable than presence-based testing?

Trust & Context

Key Stat:
Road risk similar to other prescription drugs
Evidence Grade:
Policy analysis synthesizing existing evidence. Arguments are well-supported but this is not a systematic review of driving impairment data.
Study Age:
Published in 2021; several jurisdictions have since updated their medicinal cannabis driving laws.
Original Title:
Medicinal cannabis and driving: the intersection of health and road safety policy.
Published In:
The International journal on drug policy, 97, 103307 (2021)
Database ID:
RTHC-03427

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Can medicinal cannabis patients drive?

In some jurisdictions, zero-tolerance laws mean patients can be prosecuted for THC in their system even when not impaired. This analysis argues these laws are inconsistent with how other impairing prescription drugs are regulated.

Is medicinal cannabis more dangerous for driving than other medications?

This analysis found road safety risks from medicinal cannabis appear similar to or lower than many other legal prescription medications that can impair driving, such as opioids and benzodiazepines.

Read More on RethinkTHC

Cite This Study

RTHC-03427·https://rethinkthc.com/research/RTHC-03427

APA

Perkins, Daniel; Brophy, Hugh; McGregor, Iain S; O'Brien, Paula; Quilter, Julia; McNamara, Luke; Sarris, Jerome; Stevenson, Mark; Gleeson, Penny; Sinclair, Justin; Dietze, Paul. (2021). Medicinal cannabis and driving: the intersection of health and road safety policy.. The International journal on drug policy, 97, 103307. https://doi.org/10.1016/j.drugpo.2021.103307

MLA

Perkins, Daniel, et al. "Medicinal cannabis and driving: the intersection of health and road safety policy.." The International journal on drug policy, 2021. https://doi.org/10.1016/j.drugpo.2021.103307

RethinkTHC

RethinkTHC Research Database. "Medicinal cannabis and driving: the intersection of health a..." RTHC-03427. Retrieved from https://rethinkthc.com/research/perkins-2021-medicinal-cannabis-and-driving

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.